No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Biotechnology
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which engages in the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. It also delivers off-the-shelf treatments to patients with high unmet medical need. Its product pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in Thousand Oaks, CA.
www.atarabio.comNo one on the platform currently holds 0HIY.L.
No tracked institution reports a position in 0HIY.L as of their last filing.
No one on the platform has traded 0HIY.L yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| Rev. Growth % | -6.3% | |||||
| Profit Margin % | 27.1% | -1058.3% | ||||
| Free Cash Flow Margin % | -42.2% | -785.8% | ||||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $3M | -97.7% | $-0.69 | $-1.07–$-0.45 | — | 1 |
| 2027 | $46M | +1502.5% | $0.94 | $0.62–$1.45 | — | 1 |
| 2028 | $38M | -16.2% | $0.44 | $0.29–$0.68 | — | 1 |
| 2029 | $69M | +81.6% | $1.69 | $1.11–$2.61 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 5 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-11 | $-0.32 | $-0.32 | -1.6% |
| 2026-05-12 | $-0.33 | $-0.29 | +12.0% |
| 2026-03-18 | $-0.18 | $-0.25 | -42.1% |
| 2025-11-12 | $-0.67 | $-0.32 | +52.0% |
| 2025-08-11 | $-0.07 | $0.19 | +393.0% |
| 2025-05-15 | $-1.98 | $3.50 | +276.8% |
| 2025-03-07 | $-2.86 | $-1.19 | +58.5% |
| 2024-11-13 | $-1.89 |
| $-2.93 |
| -55.2% |
| $57M |
| — |
| 0JW9.LLite Strategy, Inc. | $1.09 | +5.83% | $7M | — |
| 0KCC.LInsight Molecular Diagnostics Inc. | $3.69 | -1.86% | $119M | — |
Source: Financial Modeling Prep · peers by sector/industry